Loading...
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine kinase inhibitors (EGFR–TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at posi...
Na minha lista:
| Udgivet i: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355811/ https://ncbi.nlm.nih.gov/pubmed/28287083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms14768 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|